We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $3.37B
This Fund
S&P 500
This Quarter Est. Return
-25%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.39B
AUM Growth
–
Cap. Flow
+$2.72B
Cap. Flow %
113.56%
Top 10 Hldgs %
77.94%
Holding
271
New
271
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$1.16B
2
JD icon
JD.com
JD
+$221M
3
PDD icon
Pinduoduo
PDD
+$210M
4
BIDU icon
Baidu
BIDU
+$183M
5
NTES icon
NetEase
NTES
+$122M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 62.14%
2 Communication Services 18.47%
3 Technology 9.22%
4 Healthcare 3.01%
5 Financials 1.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HGEN
251
DELISTED
HUMANIGEN, INC.
HGEN
$149K 0.01%
+25,054
New +$352K
AGEN
252
Agenus
AGEN
$257M
$139K 0.01%
+1,351
New +$153K
CVM icon
253
CEL-SCI Corp
CVM
$20.8M
$129K 0.01%
+393
New +$115K
IBRX icon
254
ImmunityBio
IBRX
$7.3B
$123K 0.01%
+12,638
New +$139K
KDMN
255
DELISTED
Kadmon Holdings, Inc.
KDMN
$122K 0.01%
+14,053
New +$80K
MNKD icon
256
MannKind Corp
MNKD
$1.26B
$121K 0.01%
+27,776
New +$125K
KPTI icon
257
Karyopharm Therapeutics
KPTI
$162M
$119K 0.01%
+1,368
New +$142K
AKBA icon
258
Akebia Therapeutics
AKBA
$341M
$107K ﹤0.01%
+37,123
New +$106K
SGMO
259
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$100K ﹤0.01%
+11,046
New +$109K
IMGN
260
DELISTED
Immunogen Inc
IMGN
$95K ﹤0.01%
+16,798
New +$97.1K
IMVT icon
261
Immunovant
IMVT
$8.25B
$91K ﹤0.01%
+10,474
New +$94.5K
SPPI
262
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$83K ﹤0.01%
+38,190
New +$104K
VBIV
263
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$80K ﹤0.01%
+862
New +$81.9K
VSTM icon
264
Verastem
VSTM
$553M
$74K ﹤0.01%
+1,995
New +$73.3K
EPZM
265
DELISTED
Epizyme, Inc
EPZM
$68K ﹤0.01%
+13,338
New +$81K
RIGL icon
266
Rigel Pharmaceuticals
RIGL
$702M
$60K ﹤0.01%
+1,655
New +$65.1K
CPRX
267
DELISTED
Catalyst Pharmaceutical
CPRX
$57K ﹤0.01%
+10,838
New +$59.3K
TCRT icon
268
Alaunos Therapeutics
TCRT
$4.64M
$41K ﹤0.01%
+151
New +$46.2K
VTGN icon
269
VistaGen Therapeutics
VTGN
$9.45M
$38K ﹤0.01%
+459
New +$39.9K
GERN icon
270
Geron
GERN
$949M
$30K ﹤0.01%
+21,560
New +$28.8K
LCTX icon
271
Lineage Cell Therapeutics
LCTX
$252M
$28K ﹤0.01%
+11,095
New +$28.5K
7 8 9 10
11

Similar funds

VFCM
Valley Forge Capital Management Miami, Florida $3.38B AUM 15.93% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
DIA
Dana Investment Advisors Waukesha, Wisconsin $3.35B AUM 29.65% 1-Year Est. Return
5NCM
59 North Capital Management Houston, Texas $3.35B AUM 22.14% 1-Year Est. Return
TAM
Troy Asset Management London, United Kingdom $3.35B AUM 11.7% 1-Year Est. Return
CS
CapitalatWork SA Auderghem $3.35B AUM
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
QCG
Quadrant Capital Group Cincinnati, Ohio $3.34B AUM 29.16% 1-Year Est. Return

E Fund Management's Q3 2021 Portfolio in Review

Q3 2021 is the first quarter with a 13F filing on record for E Fund Management, which disclosed 271 positions worth $2.39B. Its ten largest holdings account for 78% of the portfolio.

Its largest position is Alibaba: 6,396,735 shares worth $947M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 62% of assets, followed by Communication Services and Technology.

  • E Fund Management's largest Q3 2021 buy was Alibaba: 6,396,735 shares worth $947M.
  • E Fund Management's ten largest holdings make up 78% of its $2.39B portfolio in Q3 2021.
  • E Fund Management disclosed 271 positions in Q3 2021, its first 13F filing on record.

Based on E Fund Management's 13F filing for Q3 2021, filed 12 Nov 2021.